PortfoliosLab logoPortfoliosLab logo
ISIN
US05463X1063
CUSIP
05463X106
IPO Date
Mar 27, 1990

Highlights

Market Cap
$2.31B
Enterprise Value
$2.25B
EPS (TTM)
-$0.66
Total Revenue (TTM)
$238.11M
Gross Profit (TTM)
$178.61M
EBITDA (TTM)
$5.69M
Year Range
$10.14 - $45.98
Target Price
$39.38
ROA (TTM)
-10.87%
ROE (TTM)
-12.85%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

AXGN Performance Chart

AxoGen, Inc. (AXGN) is up 36.5% since the beginning of the year. At $45 per share, AXGN is trading just below its 52-week high of $46. Investors who bought $1,000 worth of AXGN shares 5 years ago would now be looking at an investment worth $2,018.


Loading charts...

S&P 500 Index

Returns By Period

AxoGen, Inc. (AXGN) has returned 36.54% so far this year and 356.49% over the past 12 months. Looking at the last ten years, AXGN has achieved an annualized return of 21.80%, outperforming the S&P 500 Index benchmark, which averaged 13.71% per year.


AxoGen, Inc.

1D
-0.58%
1M
9.27%
YTD
36.54%
6M
36.08%
1Y
356.49%
3Y*
70.67%
5Y*
15.08%
10Y*
21.80%

Benchmark (S&P 500 Index)

1D
-1.44%
1M
-1.45%
YTD
7.60%
6M
6.59%
1Y
22.24%
3Y*
19.20%
5Y*
11.54%
10Y*
13.71%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AXGN Monthly Returns History

Based on dividend-adjusted daily data since Mar 27, 1990, AXGN's average daily return is +0.33%, while the average monthly return is +2.97%. At this rate, an investment would double in approximately 2.0 years.

Historically, 46% of months were positive and 54% were negative. The best month was May 2007 with a return of +225.0%, while the worst month was Jul 2002 at -51.3%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.

On a daily basis, AXGN closed higher 38% of trading days. The best single day was Apr 30, 2003 with a return of +150.0%, while the worst single day was Feb 13, 2003 at -58.8%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20266.48%-8.95%4.41%30.40%-8.61%13.20%36.54%
202510.50%9.88%-7.55%-12.05%-33.07%-0.37%20.65%23.30%10.53%24.55%28.94%14.24%98.60%
202441.58%9.20%-23.58%-20.57%6.55%6.00%21.27%49.77%6.62%-0.14%-0.71%18.56%141.29%
2023-5.11%-12.88%14.55%-4.55%-5.76%7.41%-5.37%-27.55%-20.13%-24.80%74.20%4.27%-31.56%
2022-7.04%7.23%-14.99%-8.82%33.56%-15.31%13.80%0.54%27.21%-4.19%-4.12%-8.86%6.51%
2021-3.07%27.38%-8.33%-7.60%8.44%6.45%-5.74%-16.25%-7.39%-3.86%-37.00%-2.09%-47.65%

Benchmark Metrics

AxoGen, Inc. has an annualized alpha of 116.20%, beta of 0.48, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since March 27, 1990.

  • This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (52.05%) than losses (50.36%) - typical of diversified or defensive assets.
  • Beta of 0.48 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
116.20%
Beta
0.48
0.00
Upside Capture
52.05%
Downside Capture
50.36%

Return for Risk

Risk / Return Rank

AXGN ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.


AXGN Risk / Return Rank: 9999
Overall Rank
AXGN Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
AXGN Sortino Ratio Rank: 9999
Sortino Ratio Rank
AXGN Omega Ratio Rank: 9898
Omega Ratio Rank
AXGN Calmar Ratio Rank: 9999
Calmar Ratio Rank
AXGN Martin Ratio Rank: 9999
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for AxoGen, Inc. (AXGN) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AXGNBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

+4.92

Sortino ratioReturn per unit of downside risk

+3.54

Omega ratioGain probability vs. loss probability

1.75

1.32

+0.43

Calmar ratioReturn relative to maximum drawdown

18.61

2.46

+16.15

Martin ratioReturn relative to average drawdown

64.69

10.92

+53.77

Dividends

Dividend History


AxoGen, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the AxoGen, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AxoGen, Inc. was 98.49%, occurring on Aug 16, 2002. Recovery took 3701 trading sessions.

The current AxoGen, Inc. drawdown is 20.05%.


Related event

Drawdown

Fall

Recovery

Underwater

Dot-com crash2000–2002
-98.49%Aug 2002
10y 11mo14y 8mo
25y 8moAug 1991 - May 2017
2023 bear market2023
-93.54%Nov 2023
5y 3mo
7y 11moJul 2018 - now
1991 bear market1991
-42.86%Jan 1991
8mo 22d2mo
10mo 22dApr 1990 - Mar 1991
2018 bear market2018
-21.42%Feb 2018
1mo 1d19d
1mo 20dJan 2018 - Feb 2018
1991 correction1991
-14.08%Aug 1991
0s8d
8dAug 1991 - Aug 1991

Drawdown Indicators


AXGNBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-98.49%

-56.78%

-41.71%

Max Drawdown (1Y)

Largest decline over 1 year

-19.30%

-9.10%

-10.20%

Max Drawdown (3Y)

Largest decline over 3 years

-61.02%

-18.90%

-42.12%

Max Drawdown (5Y)

Largest decline over 5 years

-83.67%

-25.43%

-58.24%

Max Drawdown (10Y)

Largest decline over 10 years

-93.54%

-33.92%

-59.62%

Current Drawdown

Current decline from peak

-20.05%

-3.21%

-16.84%

Average Drawdown

Average peak-to-trough decline

-64.83%

-10.71%

-54.12%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.54%

2.04%

+3.50%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of AxoGen, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how AxoGen, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AXGN relative to other companies in the Medical Devices industry. Currently, AXGN has a P/S ratio of 8.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for AXGN in comparison with other companies in the Medical Devices industry. Currently, AXGN has a P/B value of 9.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with AXGN

Add AxoGen, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with AXGN